Table 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Image 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. …”

Image 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. …”

Image 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Table 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. …”

Image 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. …”

Table 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Table 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Image 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Image 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Supplementary file 1_Efficacy and safety of the commercial Chinese polyherbal preparation Liu Shen Wan as an adjunctive treatment for herpes zoster and postherpetic neuralgia: a sy... by Yajing Li (1394572)

“…Meta-analysis demonstrated that LSW plus conventional treatment significantly outperformed conventional treatment alone in shortening vesicle cessation time [MD = −1.44, 95% CI (−1.66, −0.93), p < 0.00001, I² = 70%], accelerating scab formation (MD = −1.72, 95% CI (−2.09, −1.35), p < 0.00001, I² = 38%), reducing scab shedding time (MD = −2.22, 95% CI (−3.64, −0.80), p = 0.002, I² = 36%), decreasing time to pain resolution (MD = −2.46, 95% CI (−3.52, −1.39), p < 0.00001, I² = 0%), and shortening pain persistence duration (MD = −1.97, 95% CI (−2.49, −1.46), p < 0.00001, I² = 86%). …”

Supplementary file 2_Efficacy and safety of the commercial Chinese polyherbal preparation Liu Shen Wan as an adjunctive treatment for herpes zoster and postherpetic neuralgia: a sy... by Yajing Li (1394572)

“…Meta-analysis demonstrated that LSW plus conventional treatment significantly outperformed conventional treatment alone in shortening vesicle cessation time [MD = −1.44, 95% CI (−1.66, −0.93), p < 0.00001, I² = 70%], accelerating scab formation (MD = −1.72, 95% CI (−2.09, −1.35), p < 0.00001, I² = 38%), reducing scab shedding time (MD = −2.22, 95% CI (−3.64, −0.80), p = 0.002, I² = 36%), decreasing time to pain resolution (MD = −2.46, 95% CI (−3.52, −1.39), p < 0.00001, I² = 0%), and shortening pain persistence duration (MD = −1.97, 95% CI (−2.49, −1.46), p < 0.00001, I² = 86%). …”

Data Sheet 1_Efficacy and safety of the commercial Chinese polyherbal preparation Liu Shen Wan as an adjunctive treatment for herpes zoster and postherpetic neuralgia: a systematic... by Yajing Li (1394572)

“…Meta-analysis demonstrated that LSW plus conventional treatment significantly outperformed conventional treatment alone in shortening vesicle cessation time [MD = −1.44, 95% CI (−1.66, −0.93), p < 0.00001, I² = 70%], accelerating scab formation (MD = −1.72, 95% CI (−2.09, −1.35), p < 0.00001, I² = 38%), reducing scab shedding time (MD = −2.22, 95% CI (−3.64, −0.80), p = 0.002, I² = 36%), decreasing time to pain resolution (MD = −2.46, 95% CI (−3.52, −1.39), p < 0.00001, I² = 0%), and shortening pain persistence duration (MD = −1.97, 95% CI (−2.49, −1.46), p < 0.00001, I² = 86%). …”

Applications of Human Biostasis in Crewed Space Exploration by Josh Universe (21186797)

“…This reduction allows for smaller habitat designs, lighter spacecraft, and decreased fuel needs, ultimately reducing mission costs. …”

Image 2_Standardized aqueous extract of Abutilon theophrasti Medic. ameliorates oxidative stress and inflammatory responses against hydrochloric acid/ethanol-induced gastric ulcer... by Hui Guo (110581)

“…Overall, the presented results greatly supported and validated the essential inflammation and oxidation events implicated in the mechanistic investigation using bioinformatics.…”

Image 1_Standardized aqueous extract of Abutilon theophrasti Medic. ameliorates oxidative stress and inflammatory responses against hydrochloric acid/ethanol-induced gastric ulcer... by Hui Guo (110581)

“…Overall, the presented results greatly supported and validated the essential inflammation and oxidation events implicated in the mechanistic investigation using bioinformatics.…”